Tirzepatide
Also searched as: Mounjaro · Zepbound
Tirzepatide activates two receptors, GIP and GLP-1, where semaglutide targets one. It is a licensed medicine in the UK, sold as Mounjaro, and is prescription-only. It has been through the full clinical trial process, which places it in a completely different evidential category from the research compounds elsewhere on this site.
What the research has looked at
- The SURPASS randomised trial programme in type 2 diabetes
- The SURMOUNT trials in weight management
- Head-to-head comparison against semaglutide
- Cardiovascular and long-term safety follow-up
This is a description of what has been studied, not a claim about what it does. Evidence level: human trials.
Legal position in the UK
Not a licensed medicine in the UKPrescription-only medicine. Legal supply requires a prescription through a registered pharmacy, with prescriber oversight.
Handling and storage
The licensed product is supplied ready to use in a manufactured device. It is not a powder and is not reconstituted.
Vial sizes: Supplied as a licensed pre-filled device, not a vial. Where a manufacturer supplies handling instructions, those take precedence over anything general.
Questions
- How does tirzepatide differ from semaglutide?
- Tirzepatide acts on two receptors, GIP and GLP-1; semaglutide acts on GLP-1 alone. Head-to-head trials have compared them directly. Both are licensed prescription medicines in the UK.
- Is it available without a prescription?
- No, and it should not be. It is a prescription-only medicine and requires a prescriber.